Animal Use Strategies in the Longshan Mountain Region of Northern China during the First Millennium BC: A Zooarchaeological Analysis of Yucun.

The first millennium BC saw the expansion of the Western Zhou dynasty in its northwestern frontier, alongside the rise and development of the Qin State in the Longshan Mountain region of northern China. Exploring the subsistence practices of these communities is crucial to gaining a better understanding of the social, cultural, and political landscape in this region at the time. While much of the research to date has focused on the Qin people, the subsistence practices of the Zhou people remain poorly understood. In this study, we analyzed animal remains from Yucun, a large settlement site associated with the Zhou people, located to the east of the Longshan Mountain. These animal remains were recovered in the excavation seasons of 2018-2020. Our results show that pigs, dogs, cattle, caprines, and horses, which were the major domestic animals at Yucun, accounted for over 90.8% of the animal remains examined in terms of the number of identified specimens (NISP) and 72.8% in terms of the minimum number of individuals (MNI), with cattle and caprines playing dominant roles. In terms of the taxonomic composition and the mortality profiles of pigs, caprines, and cattle, Yucun shared similarities with Maojiaping and Xishan, two contemporaneous Qin cultural sites located to the west of the Longshan Mountain, and differ from other farming societies in the middle and lower reaches of the Yellow River valley. Considering the cultural attributes and topographic conditions of these various sites, these findings imply that environmental conditions may have played a more significant role than cultural factors in shaping the animal-related subsistence practices in northern China during the first millennium BC.

Bistratal Au@Bi2S3 nanobones for excellent NIR-triggered/multimodal imaging-guided synergistic therapy for liver cancer.

To fabricate a highly biocompatible nanoplatform enabling synergistic therapy and real-time imaging, novel Au@Bi2S3 core shell nanobones (NBs) (Au@Bi2S3 NBs) with Au nanorods as cores were synthesized. The combination of Au nanorods with Bi2S3 film made the Au@Bi2S3 NBs exhibit ultrahigh photothermal (PT) conversion efficiency, remarkable photoacoustic (PA) imaging and high computed tomography (CT) performance; these Au@Bi2S3 NBs thus are a promising nanotheranostic agent for PT/PA/CT imaging. Subsequently, poly(N-vinylpyrrolidone)-modified Au@Bi2S3 NBs (Au@Bi2S3-PVP NBs) were successfully loaded with the anticancer drug doxorubicin (DOX), and a satisfactory pH sensitive release profile was achieved, thus revealing the great potential of Au@Bi2S3-PVP NBs in chemotherapy as a drug carrier to deliver DOX into cancer cells. Both in vitro and in vivo investigations demonstrated that the Au@Bi2S3-PVP NBs possessed multiple desired features for cancer therapy, including extremely low toxicity, good biocompatibility, high drug loading ability, precise tumor targeting and effective accumulation. Highly efficient ablation of the human liver cancer cell HepG2 was achieved through Au@Bi2S3-PVP NB-mediated photothermal therapy (PTT). As both a contrast enhancement probe and therapeutic agent, Au@Bi2S3-PVP NBs provided outstanding NIR-triggered multi-modal PT/PA/CT imaging-guided PTT and effectively inhibited the growth of HepG2 liver cancer cells via synergistic chemo/PT therapy.

Potent anticancer activity of a new bismuth (III) complex against human lung cancer cells.

The aim of this work is experimental study of an interesting bismuth(III) complex derived from pentadentate 2,6-pyridinedicarboxaldehyde bis(4N-methylthiosemicarbazone), [BiL(NO3)2]NO3 {L=2,6-pyridinedicarboxaldehyde bis(4N-methylthiosemicarbazone)}. A series of in vitro biological studies indicate that the newly prepared [BiL(NO3)2]NO3 greatly suppressed colony formation, migration and significantly induced apoptosis of human lung cancer cells A549 and H460, but did not obviously decrease the cell viability of non-cancerous human lung fibroblast (HLF) cell line, showing much higher anticancer activities than its parent ligands, especially with half maximum inhibitory concentration (IC50) <3.5µM. Moreover, in vivo study provides enough evidence that the treatment with [BiL(NO3)2]NO3 effectively inhibited A549 xenograft tumor growth on tumor-bearing mice (10mgkg-1, tumor volume reduced by 97.92% and tumor weight lightened by 94.44% compared to control) and did not indicate harmful effect on mouse weight and liver. These results suggest that the coordination of free ligand with Bi(III) might be an interesting and potent strategy in the discovery of new anticancer drug candidates.

Improvement in the Anticancer Activity of 6-Mercaptopurine via Combination with Bismuth(III).

6-Mercaptopurine (6-MP) is a clinically important antitumor drug and its commercially available form is provided as monohydrate, belonging to biopharmaceuticals classification system (BCS) class II category. The combination of bismuth(III) (Bi(III)) with 6-MP was proved to significantly improve the anticancer activity of 6-MP, leading to the discovery of a new amorphous complex ([Bi(MP)3(NO3)2]NO3). The prepared [Bi(MP)3(NO3)2]NO3 was characterized by the matrix assisted laser desorption-ionization time-of-flight (MALDI-TOF)-MS, etc. Noticeably, according to the in vitro evaluations of cytotoxicity, cellular apoptotic, colony formation as well as cell migration, the anticancer activity of amorphous [Bi(MP)3(NO3)2]NO3 was found to be of high therapeutic effect over 6-MP.